Philadelphia/ Health & Lifestyle

Breckenridge Recalls One Propranolol Lot Over Possible Metal

AI Assisted Icon
Published on November 18, 2026
Breckenridge Recalls One Propranolol Lot Over Possible Metal7722 Dungan Rd. — Reported Manufacturer of Recalled Capsules
Google Street View

A blood-pressure capsule that can sit in a medicine cabinet until May 2029 is already the subject of a nationwide pull, and the warning is not about a missed dose. It is about possible metal.

New Jersey-based Breckenridge Pharmaceutical said Monday it is voluntarily recalling one lot of 60 mg propranolol hydrochloride extended-release capsules to the consumer level. In its announcement, the company said use of the affected lot could potentially cause lacerations of soft tissues in the oral cavity, esophagus, stomach, or intestine. Philadelphia-based Adare Pharma Solutions manufactured the capsules.

The Lot That Shipped

The recalled product went to wholesalers and pharmacies nationwide between October 26 and November 4, in 100-count bottles. EMPR reported the identifiers patients and pharmacists can actually check: NDC 51991-817-01, lot PK25110035, expiration May 2029.

That date is the practical problem. A bottle filled this fall does not look expired, and nothing in the company's notice limits the recall to a single city or pharmacy chain. There is also no published count of how many bottles left the warehouse.

Caught Next Door, Not in This Bottle

Breckenridge did not say inspectors had pulled a confirmed metal fragment out of lot PK25110035. It said the affected lot shared intermediate material suspected to be the source of metal contamination identified in a separate lot. That other lot was not released to market.

So the lot that never shipped is what flagged the problem. The lot that did ship shared the material now under suspicion. The company has not identified the type or amount of metal, and it said it was not aware of any adverse events assessed to be related to this recall.

Breckenridge also said the recall is being conducted with the knowledge of the U.S. Food and Drug Administration. That is the company's statement.

Stop the Capsules, Don't Improvise a Substitute

Consumers should immediately stop taking product from the recalled lot and contact a physician or other health care provider for medical advice and replacement instructions. This is a blood-pressure medicine. The notice does not tell patients to quit treatment on their own or to swap in whatever capsule is left in the cabinet.

USA Today reported that wholesalers, pharmacies, and other retailers were told to check inventories, quarantine the recalled lot, and stop distributing it. Anyone still holding a 60 mg extended-release bottle should match the NDC, the lot number, and the May 2029 date before assuming the warning applies.

Not the Only Blood-Pressure Pull This Year

The failure mode here is different from a pill that simply does not dissolve. The Houston Chronicle reported three recalls involving blood-pressure medications from different manufacturers since May, citing dissolution problems and impurities.

Those are not the same event as this metal warning. USA Today reported that Advagen Pharma Limited recalled 3,684 bottles of 50 mg metoprolol tartrate tablets in late October because they may have contained foreign tablets or capsules, and that Macleods Pharmaceuticals recalled some tablets on October 7 for failed dissolution specifications, meaning the drug does not release its active ingredients properly. NBC Philadelphia also described an earlier-this-month recall of olmesartan medoxomil, amlodipine, and hydrochlorothiazide tablets that did not dissolve properly, plus thousands of bottles of chlorthalidone recalled earlier in the fall for the same dissolution problem.

For this propranolol lot, the next useful step is narrower than the trend. Match the bottle. If it is PK25110035, stop taking it and get replacement instructions from a clinician before the May 2029 date makes an old fill look perfectly fine.